Detalhe da pesquisa
1.
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Haematologica;
105(6): 1650-1659, 2020 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31515355
2.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Blood;
127(9): 1109-16, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26802176
3.
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
Haematologica;
105(12): 2879-2882, 2020 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33256392
4.
The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation.
Acta Haematol;
133(1): 116-23, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25247397
5.
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Cancers (Basel);
16(5)2024 Feb 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38473382
6.
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
Hemasphere;
7(9): e940, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37663673